#United States #New York #Rosen Law Firm #Sarepta Therapeutics #ELEVIDYS

Investors Seek Leadership Roles in Sarepta Therapeutics Fraud Case

In a breaking development within the realm of securities law, stakeholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are being urged to take action as part of an important class action lawsuit concerning alleged securities fraud. The Rosen Law Firm, renowned for advocating investor rights globally, has highlighted that individuals who purchased securities between June 22, 2023, and June 24, 2025—inclusive of these dates—are eligible to participate in this potentially significant litigation.

Why Participate in the Class Action?

The class action aims to address the alleged wrongdoings by the company during the specified period. The deadline for those interested in serving as lead plaintiffs is August 25, 2025, making it imperative for interested investors to act promptly. Individuals who invested in Sarepta during the identified 'Class Period' may be entitled to compensation without incurring out-of-pocket costs due to a contingency fee arrangement, presenting a low-risk opportunity for those seeking to recover losses impacted by the alleged misrepresentation in the company's disclosures.

Next Steps for Investors

To join this significant legal pursuit, investors can visit the Rosen Law Firm's dedicated class action page or contact Phillip Kim, Esq., for further information regarding the lawsuit. As stated in the announcement, interested individuals should navigate to Rosen Legal or call 866-767-3653. The call to action clearly indicates that despite the class having yet to be certified, investors still have the option of selecting counsel or remaining uninvolved.

Overview of the Allegations Against Sarepta

The allegations underpinning this class action are serious and concerning. According to court documents, the plaintiffs assert that throughout the Class Period, Sarepta Therapeutics and its affiliates made numerous misleading statements and inadequately disclosed critical information regarding their ELEVIDYS trial involving a gene therapy meant for patients with Duchenne muscular dystrophy. The following points summarize the allegations:
1. ELEVIDYS exhibited significant safety concerns that were not disclosed to investors;
2. The trial protocols were inadequate in identifying severe side effects from treatment;
3. Sarepta halted the recruitment and dosing in the trials due to the discovery of adverse events, leading to regulatory scrutiny;
4. Consequently, these issues materially misled investors by presenting a false sense of security regarding the therapeutic's approval process and commercial viability.

The core of the lawsuit revolves around this allegedly misleading information, and the resulting investor losses when the truth came to light.

Why Rosen Law Firm?

The decision to engage with Rosen Law Firm carries weight due to their established track record in handling securities class actions. The firm has achieved notable success, including the largest securities class action settlement against a Chinese company at the time. They also have consistently ranked highly for settlements throughout the years—securing over $438 million for investors in 2019 alone—and have been recognized for their efforts in litigating on behalf of shareholders worldwide. The firm emphasizes the importance of selecting qualified legal counsel and has urged investors to consider their well-regarded experience when choosing representation.

As news unfolds, Rosen Law Firm will continue to provide updates through their various social media channels including LinkedIn, Twitter, and Facebook. Investors are advised to stay informed for the latest developments in this ongoing lawsuit.

Engagement in this lawsuit not only serves to potentially recoup losses for investors but also acts as a crucial moment in holding corporations accountable for transparent practices in their disclosures.

• ---

For more information about the class action against Sarepta Therapeutics, contact The Rosen Law Firm, P.A. at their New York office— 275 Madison Avenue, 40th Floor, NY 10016, or call (212) 686-1060.

Note: Participation in this class action may precede formal certification. Investors are advised to consult with qualified legal counsel before making a decision.